DNAY - Codex DNA, Inc. Stock Price, Fair Value and News

4.50USD0.00 (0.00%)Market Closed

Market Summary

USD4.500.00

Market Closed

0.00%

DNAY Stock Price

View Fullscreen

DNAY RSI Chart

DNAY Valuation

Market Cap

135.5M

Price/Earnings (Trailing)

-2.99

Price/Sales (Trailing)

5.5

EV/EBITDA

-3.21

Price/Free Cashflow

-4.71

DNAY Price/Sales (Trailing)

DNAY Profitability

Operating Margin

60.43%

EBT Margin

-183.57%

Return on Equity

549.32%

Return on Assets

-71.44%

Free Cashflow Yield

-21.22%

DNAY Fundamentals

DNAY Revenue

Revenue (TTM)

24.6M

Rev. Growth (Yr)

-45.54%

Rev. Growth (Qtr)

-50.7%

DNAY Earnings

Earnings (TTM)

-45.2M

Earnings Growth (Yr)

22.32%

Earnings Growth (Qtr)

51.17%

Breaking Down DNAY Revenue

Last 7 days

-11.1%

Last 30 days

1084.2%

Last 90 days

1306.3%

Trailing 12 Months

119.5%

How does DNAY drawdown profile look like?

DNAY Financial Health

Current Ratio

3.65

Debt/Equity

-0.63

Debt/Cashflow

-5.12

DNAY Investor Care

Shares Dilution (1Y)

1.36%

Diluted EPS (TTM)

-6.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	24.6M	0	0	0
2023	28.1M	31.1M	30.0M	27.5M
2022	14.4M	17.2M	21.0M	27.4M
2021	7.7M	8.8M	9.9M	11.0M
2020	0	0	0	6.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Codex DNA, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 11, 2022	nelson todd robert	bought	191,542	1.5634	122,516	president & ceo
Jul 20, 2022	tumolo annette	acquired	-	-	74,611	-
Jun 09, 2022	nachtsheim jami k	acquired	-	-	20,630	-
Jun 09, 2022	tsingos christine a	acquired	-	-	20,630	-
Jun 09, 2022	snider william	acquired	-	-	20,630	-
Jun 09, 2022	witney frank	acquired	-	-	20,630	-
Jun 09, 2022	jackson andrea liapis	acquired	-	-	20,630	-
Jun 22, 2021	danaher corp /de/	acquired	-	-	2,294,160	-
Jun 22, 2021	snider william	acquired	-	-	1,319,040	-
Jun 22, 2021	broadoak fund iv, llc	acquired	-	-	1,319,040	-

Which funds bought or sold DNAY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	894	9,592	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-14,957	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-49.2	-	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	2,747	29,480	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-21.89	-16,458	102,254	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	13,400	1,357	1,366	-%
May 15, 2024	DAGCO, INC.	sold off	-100	-986	-	-%
May 15, 2024	Dynamic Wealth Strategies, LLC	unchanged	-	14.00	1,000	-%
May 15, 2024	Northpond Ventures, LLC	unchanged	-	403,609	4,331,420	4.22%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.15	242	2,640	-%

Are Funds Buying or Selling DNAY?

Are funds buying DNAY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DNAY

No. of Funds

Unveiling Codex DNA, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jul 05, 2023	broadoak fund iv, llc	10.35%	4,434,730	SC 13G/A
Jul 05, 2023	gattaca mining llc	21.28%	9,273,521	SC 13G/A
Jun 15, 2023	novalis lifesciences investments ii, l.p.	19.99%	7,419,984	SC 13D
Jun 07, 2023	northpond ventures, lp	46.7%	17,838,123	SC 13D/A
Jun 02, 2023	northpond ventures, llc	31.5%	9,375,380	SC 13D/A
Apr 19, 2023	northpond ventures, lp	31.6%	9,375,380	SC 13D/A
Feb 14, 2023	gattaca mining llc	21.2%	6,271,113	SC 13G/A
Jan 27, 2023	danaher corp /de/	7.8%	2,294,157	SC 13G/A

Recent SEC filings of Codex DNA, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 06, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
Apr 23, 2024	ARS	ARS
Apr 19, 2024	4	Insider Trading

Codex DNA, Inc. News

Latest updates

Codex DNA, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-50.7%	3,440,000	6,977,000	5,564,000	8,652,000	6,316,000	9,469,000	6,675,000	5,655,000	5,636,000	3,078,000	2,786,000	2,852,000	2,327,000	1,981,000	1,635,000	1,617,000
Cost Of Revenue	-10.5%	1,994,000	2,228,000	2,567,000	2,959,000	2,805,000	3,023,000	3,016,000	2,943,000	2,858,000	2,196,000	1,624,000	1,899,000	1,025,000	-	739,000	620,000
Gross Profit	-69.6%	1,446,000	4,749,000	2,997,000	5,693,000	3,511,000	6,446,000	3,659,000	2,712,000	2,778,000	882,000	1,162,000	953,000	1,302,000	-	896,000	997,000
Operating Expenses	-55.2%	9,967,000	22,230,000	13,118,000	13,659,000	14,482,000	14,330,000	14,910,000	17,199,000	15,641,000	12,979,000	10,603,000	8,525,000	7,566,000	-	5,196,000	4,293,000
S&GA Expenses	-53.5%	1,675,000	3,604,000	2,743,000	3,360,000	3,807,000	4,108,500	4,189,000	4,688,000	3,546,000	3,087,500	2,955,000	2,630,000	2,275,000	-	1,861,000	1,598,000
R&D Expenses	-20.3%	2,925,000	3,669,000	4,119,000	4,587,000	5,121,000	4,707,000	5,460,000	6,950,000	6,305,000	5,249,000	3,593,000	2,746,000	2,878,000	-	2,345,000	1,955,000
EBITDA Margin	-6.1%	-1.64	-1.55	-1.11	-1.15	-1.53	-1.65	-2.42	-2.83	-3.01	-3.41	-1.73	-1.95	-2.23	-	-	-
Interest Expenses	-88.5%	162,000	1,405,000	645,000	546,000	509,000	1,138,000	241,000	303,000	273,000	276,000	279,000	107,000	163,000	-	-	-
Income Taxes	-33.3%	2,000	3,000	14,000	4,000	3,000	6,000	6,000	6,000	6,000	4,000	4,000	2,000	4,000	-	2,000	-
Earnings Before Taxes	51.2%	-8,635,000	-17,684,000	-10,617,000	-8,283,000	-11,116,000	-8,126,000	-12,308,000	-14,825,000	-13,188,000	-12,487,000	-9,820,000	-9,199,000	-7,438,000	-	-4,463,000	-4,082,000
EBT Margin	-5.9%	-1.84	-1.73	-1.27	-1.28	-1.65	-1.77	-2.51	-2.93	-3.11	-3.53	-1.81	-2.04	-2.34	-	-	-
Net Income	51.2%	-8,637,000	-17,687,000	-10,631,000	-8,287,000	-11,119,000	-8,132,000	-12,314,000	-14,831,000	-13,194,000	-12,491,000	-9,824,000	-9,201,000	-7,442,000	-5,583,000	-4,465,000	-4,082,000
Net Income Margin	-5.9%	-1.84	-1.73	-1.27	-1.28	-1.65	-1.77	-2.51	-2.93	-3.12	-3.53	-3.23	-3.03	-2.80	-	-	-
Free Cashflow	50.6%	-3,739,000	-7,564,000	-5,992,000	-11,454,000	-11,637,000	-6,402,000	-15,494,000	-15,206,000	-6,081,000	-13,795,000	-12,984,000	-6,557,000	-5,216,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-10.1%	63.00	70.00	105	115	89.00	81.00	88.00	97.00	111	116	124	136	27.00
Current Assets	-22.9%	23.00	30.00	53.00	62.00	43.00	55.00	62.00	72.00	88.00	93.00	117	127	17.00
Cash Equivalents	583.0%	11.00	2.00	17.00	47.00	23.00	30.00	25.00	22.00	31.00	83.00	110	124	13.00
Inventory	-8.8%	4.00	4.00	4.00	4.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	1.00	1.00
Goodwill	0%	3.00	3.00	15.00	15.00	15.00	15.00	15.00	14.00	14.00	14.00	4.00	3.00	3.00
Liabilities	2.0%	42.00	41.00	59.00	58.00	53.00	35.00	35.00	33.00	33.00	25.00	22.00	24.00	13.00
Current Liabilities	-21.7%	6.00	8.00	25.00	10.00	11.00	13.00	13.00	18.00	16.00	10.00	8.00	7.00	6.00
Long Term Debt	-0.9%	5.00	5.00	5.00	20.00	20.00	20.00	19.00	11.00	12.00	14.00	14.00	14.00	3.00
LT Debt, Current	-	-	-	15.00	-	-	-	-	4.00	2.00	1.00	1.00	-	1.00
LT Debt, Non Current	-100.0%	-	5.00	5.00	20.00	20.00	20.00	19.00	11.00	12.00	14.00	14.00	14.00	3.00
Shareholder's Equity	-3560.5%	-8.24	0.00	18.00	28.00	37.00	47.00	53.00	65.00	78.00	91.00	103	112	-
Retained Earnings	-5.3%	-170	-161	-143	-133	-124	-113	-105	-93.29	-78.46	-65.27	-52.78	-42.95	-26.31
Additional Paid-In Capital	0.1%	162	162	162	161	161	160	159	158	157	156	156	155	1.00
Shares Outstanding	0.1%	30.00	30.00	30.00	30.00	30.00	30.00	29.00	29.00	29.00	29.00	14.00	7.00	-
Float	-	-	-	-	14.00	-	-	-	17.00	-	-	-	201	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	55.7%	-3,237	-7,312	-5,888	-10,300	-11,167	-5,639	-15,103	-12,351	-5,622	-12,439	-12,651	-6,491	-5,117	-	-	-
Share Based Compensation	24.4%	766	616	1,156	1,035	1,156	1,246	915	1,118	448	508	365	146	67.00	-	-	-
Cashflow From Investing	88.6%	12,248	6,495	-23,208	6,846	4,123	11,209	13,724	2,943	-45,883	-14,542	-333	-66.00	-99.00	-	-	-
Cashflow From Financing	99.8%	-27.00	-15,021	-101	26,705	-18.00	108	4,013	331	58.00	-15.00	-985	112,494	9,587	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

DNAY Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 3,440	$ 6,316
Cost of revenue	1,994	2,805
Gross profit	1,446	3,511
Operating expenses:
Research and development	2,925	5,121
Sales and marketing	1,675	3,807
General and administrative	5,367	5,554
Total operating expenses	9,967	14,482
Loss from operations	(8,521)	(10,971)
Other (expense) income, net:
Interest income	228	390
Interest expense	(217)	(639)
Change in fair value of derivative liabilities	0	140
Other expense, net	(125)	(36)
Total other expense, net	(114)	(145)
Loss before provision for income taxes	(8,635)	(11,116)
Provision for income taxes	(2)	(3)
Net loss	(8,637)	(11,119)
Less: redeemable convertible preferred stock dividends	(585)
Net loss attributable to common stockholders	$ (9,222)	$ (11,119)
Net loss per share attributable to common stock holders
Basic (in dollars per share)	$ (5.52)	$ (6.75)
Diluted (in dollars per share)	$ (5.52)	$ (6.75)
Weighted average common stock outstanding
Basic (in shares)	1,670,981	1,647,945
Diluted (in shares)	1,670,981	1,647,945
Net loss	$ (8,637)	$ (11,119)
Unrealized (loss) gain on available-for-sale short-term investments	(4)	5
Foreign currency translation loss	(6)
Total comprehensive loss	(8,647)	(11,114)
Product revenue
Revenue:
Total revenue	1,264	3,001
Service revenue
Revenue:
Total revenue	1,251	1,674
Collaboration revenue
Revenue:
Total revenue		962
Royalties and other revenue
Revenue:
Total revenue	$ 925	$ 679

DNAY Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 10,623	$ 1,570
Restricted cash	100	175
Short-term investments	4,973	17,588
Accounts receivable, net of allowance for credit losses of $1,269 and $1,287 at March 31, 2024 and December 31, 2023, respectively	2,997	5,985
Inventory, net	3,669	4,025
Prepaid expenses and other current assets	1,033	1,008
Total current assets	23,395	30,351
Property and equipment, net	6,683	7,300
Right-of-use assets	28,289	27,220
Other long-term assets	228	676
Goodwill	3,497	3,497
Other intangible assets, net	1,239	1,367
Total assets	63,331	70,411
Current liabilities:
Accounts payable	1,905	3,284
Accrued employee expenses	2,411	2,142
Finance lease liability, current portion	115	112
Operating lease liability, current portion	879	1,710
Deferred revenue, current portion	375	338
Other accrued liabilities	680	506
Other current liabilities	47	92
Total current liabilities	6,412	8,184
Finance lease liability, net of current portion	125	147
Operating lease liability, net of current portion	29,776	27,142
Notes payable, net of discount	5,223	5,269
Derivative liabilities	36	36
Deferred revenue, net of current portion	110	95
Total liabilities	41,682	40,873
Commitments and contingencies (Note 14)
Preferred stock, $0.0001 par value; 5,000,000 shares authorized: Redeemable convertible preferred stock, 280,000 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively; liquidation preference of $29,885 and $29,300 at March 31, 2024 and December 31, 2023, respectively	29,885	29,300
Stockholders' (deficit) equity
Common stock, $0.0001 par value; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 1,672,405 and 1,670,185 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	161,876	161,703
Accumulated other comprehensive loss	(10)
Accumulated deficit	(170,102)	(161,465)
Total stockholders' (deficit) equity	(8,236)	238
Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity	$ 63,331	$ 70,411

About Codex DNA, Inc.

WEBSITE	https://codexdna.com

Codex DNA, Inc. Frequently Asked Questions

What is the ticker symbol for Codex DNA, Inc.? What does DNAY stand for in stocks?

DNAY is the stock ticker symbol of Codex DNA, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Codex DNA, Inc. (DNAY)?

As of Fri May 17 2024, market cap of Codex DNA, Inc. is 135.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNAY stock?

You can check DNAY's fair value in chart for subscribers.

What is the fair value of DNAY stock?

You can check DNAY's fair value in chart for subscribers. The fair value of Codex DNA, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Codex DNA, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNAY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Codex DNA, Inc. a good stock to buy?

The fair value guage provides a quick view whether DNAY is over valued or under valued. Whether Codex DNA, Inc. is cheap or expensive depends on the assumptions which impact Codex DNA, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNAY.

What is Codex DNA, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, DNAY's PE ratio (Price to Earnings) is -2.99 and Price to Sales (PS) ratio is 5.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNAY PE ratio will change depending on the future growth rate expectations of investors.